Corcept Therapeutics (CORT) Net Margin (2012 - 2026)

Corcept Therapeutics has disclosed Net Margin across 15 years of filings, most recently posting 18.92% for Q1 2026.

• Net Margin for Q1 2026 came in at 18.92%, down 3183.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.07% (down 1326.0% YoY), and the FY2025 annual result was 12.89%, down 781.0% from the prior year.
• Net Margin came in at 18.92% for Q1 2026 at Corcept Therapeutics, down from 11.83% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 33.96% in Q3 2022 to a low of 18.92% in Q1 2026.
• The 5-year median for Net Margin is 18.74% (2024), against an average of 17.8%.
• Across the five-year window, Net Margin soared 696 bps in 2023 and sank 3183 bps in 2026, its largest moves.
• Corcept Therapeutics' Net Margin stood at 16.04% in 2022, then soared by 43 bps to 23.0% in 2023, then retreated by 27 bps to 16.71% in 2024, then retreated by 29 bps to 11.83% in 2025, then plunged by 260 bps to 18.92% in 2026.
• The last three Net Margin figures came in at 18.92% (Q1 2026), 11.83% (Q4 2025), and 9.32% (Q3 2025), per Business Quant data.